Meta-analysis - Eltrombopag

Systematic Review of the Clinical and Cost Effectiveness of Treatments for Idiopathic (Immune) Thrombocytopenic Purpura (ITP): Direct Meta Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01235988

Enrollment

Registered

2010-11-08

Start date

2009-08-31

Completion date

2009-10-31

Last updated

2017-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopaenia

Brief summary

The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)

Detailed description

Meta-analysis of three studies: Bussell 2007 & Bussell 2009 & RAISE (TRA102537).

Interventions

DRUGEltrombopag

Eltrombopag 50mg & standard of care

DRUGPlacebo

Placebo + standard of care

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults with ITP * Received a pre-specified treatment * Prospective clinical studies with at least 10 patients

Exclusion criteria

* Subjects with ITP due to other causes

Design outcomes

Primary

Measure	Time frame
>=50 Gi/L platelet count to <400 Gi/L	43 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026